Leukemia

Patients with IDH1-mutant relapsed/refractory acute myeloid leukemia achieved a notable complete response rate following treatment with olutasidenib.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma achieved promising early responses following treatment with BCB-11417 with or without zanubrutinib.

Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.

Blinatumomab plus consolidation chemotherapy produced a 58% reduction in the risk of death vs consolidation chemotherapy alone in patients with MRD-negative B-cell acute lymphoblastic leukemia.

Results from the phase 3 ALPINE trial found improved progression-free survival and overall response rate when Zanubrutinib was given to patients with chronic lymphocytic leukemia or small lymphatic leukemia vs ibrutinib.

The average time to next treatment among patients with chronic lymphocytic leukemia occurred faster in those treated with acalabrutinib vs ibrutinib.

Magrolimab in combination with azacitidine and venetoclax was well tolerated and yielded promising responses among patients with high-risk acute myeloid leukemia regardless of TP53 mutation status.

Ziftomenib monotherapy showed pronounced antileukemic activity and a tolerable toxicity profile in pretreated patients with relapsed/refractory acute myeloid leukemia.

Patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia, chronic phase, or acute phase who are resistant to tyrosine kinase inhibitors were found to show a clinical benefit with olvermbatinib.

A potential efficacy benefit has been observed with lintuzumab-Ac225 plus salvage therapy for patients with relapsed/refractory acute myeloid leukemia.

The phase 3 ASAP trial found the use of watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation found a similar survival benefit in patients with relapsed/refractory acute myeloid leukemia.

Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.

The FDA’s approval of oral olutasidenib provides adults with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation a new treatment option.

The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.

The European Commission based its approval of zanubrutinib for the management of chronic lymphocytic leukemia on data from the phase 3 SEQUOIA trial and the phase 3 ALPINE trial.

Patients with acute lymphocytic leukemia or lymphoblastic lymphoma can now receive asparaginase erwinia chrysanthemi at 25 mg/m2 on Monday and Wednesday followed by 50 mg/m2 on Friday, or 25 mg/m2 every 48 hours.

Among patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, ponatinib plus chemotherapy yielded higher rates of minimal residual disease–negative complete remission compared with imatinib.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).

The Memorial Sloan Kettering team gets their chance to question the Dana-Farber team on the datasets they presented.

Findings from a secondary analysis highlighted an association between improved quality of life outcomes and longitudinal use of approach-oriented coping strategies in patients with acute myeloid leukemia.

Dr DeAngelo shares data on the use of ponatinib for CML treatment after failure of second-generation TKIs.

Daniel DeAngelo, MD, PhD, presents data from a phase 3 study comparing asciminib and bosutinib after treatment with 2 or more prior TKIs in CML.

A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission compared with conventional care in elderly patients with relapsed or refractory acute myeloid leukemia.

The Dana-Farber team puts Memorial Sloan Kettering to the test and questions the panel on the presented abstracts.

Dr Michael Mauro continues his presentation with a look at an analysis of the arterial occlusive events in the PACE trial in CML.